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Abstract
Background: Mucin type O-glycosylation is one of the most common types of post-translational modifications that
impacts stability and biological functions of many mammalian proteins. A large family of UDP-GalNAc polypeptide:
N-acetyl-a-galactosaminyltransferases (GalNAc-Ts) catalyzes the first step of mucin type O-glycosylation by
transferring GalNAc to serine and/or threonine residues of acceptor polypeptides. Plants do not have the enzyme
machinery to perform this process, thus restricting their use as bioreactors for production of recombinant
therapeutic proteins.
Results: The present study demonstrates that an isoform of the human GalNAc-Ts family, GalNAc-T2, retains its
localization and functionality upon expression in N. benthamiana L. plants. The recombinant enzyme resides in the
Golgi as evidenced by the fluorescence distribution pattern of the GalNAc-T2:GFP fusion and alteration of the
fluorescence signature upon treatment with Brefeldin A. A GalNAc-T2-specific acceptor peptide, the 113-136 aa
fragment of chorionic gonadotropin b-subunit, is glycosylated in vitro by the plant-produced enzyme at the
“native” GalNAc attachment sites, Ser-121 and Ser-127. Ectopic expression of GalNAc-T2 is sufficient to “arm”
tobacco cells with the ability to perform GalNAc-glycosylation, as evidenced by the attachment of GalNAc to Thr-
119 of the endogenous enzyme endochitinase. However, glycosylation of highly expressed recombinant
glycoproteins, like magnICON-expressed E. coli enterotoxin B subunit:H. sapiens mucin 1 tandem repeat-derived
peptide fusion protein (LTBMUC1), is limited by the low endogenous UDP-GalNAc substrate pool and the
insufficient translocation of UDP-GalNAc to the Golgi lumen. Further genetic engineering of the GalNAc-T2 plants
by co-expressing Y. enterocolitica UDP-GlcNAc 4-epimerase gene and C. elegans UDP-GlcNAc/UDP-GalNAc
transporter gene overcomes these limitations as indicated by the expression of the model LTBMUC1 protein
exclusively as a glycoform.
Conclusion: Plant bioreactors can be engineered that are capable of producing Tn antigen-containing
recombinant therapeutics.
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Background
Plants emerged as effective systems for production of
pharmaceutically important mammalian proteins, and a
number of transgenic plant-based products are currently
available in the market [1]. Work in the field of plant
molecular farming revealed that, while there are obvious
advantages to using plant bioreactors, including low
cost, fast scalability, biological safety, proper protein
folding and assembly, there are also some limitations.
Glycosylation differences between plants and humans is
one of the major drawbacks that can negatively influ-
ence properties of plant-derived recombinant proteins
[2,3]. Significant efforts have been made to “humanize”
plant N-glycan structures, either by retaining the recom-
binant proteins in the endoplasmic reticulum (ER) [4] or
by modifying the enzyme machinery in the Golgi appa-
ratus to eliminate plant-specific b(1, 2)-xylose and a
(1,3)-fucose residues [5] and extend plant N-glycans
with terminal b(1, 4)-galactose residues [6]. However,
little attention has been paid to the structural differ-
ences between plant and mammalian O-glycans.
O-glycans are attached primarily to hydroxyproline
(Hyp) and serine residues in plant glycoproteins. Typi-
cally, non-contiguous Hyp residues are modified with
arabinogalactan polysaccharides, whereas contiguous
Hyp are exclusively arabinosylated [7,8]. The extent of
proline hydroxylation and Hyp glycosylation depends on
the side chains of flanking amino acids [8]. A specific
motif ([not basic]-[not T]-[AVSG]-Pro-[AVST]-
[GAVPSTC]-[APS]) has been defined, based on examina-
tion of amino acid sequence requirements, for efficient
hydroxylation of proline and arabinogalactosylation of
Hyp [9]. No rules for selection of serine residues for
O-glycosylation have been defined so far, probably
because the number of identified proteins with glycosy-
lated serines is still limited to a few plant lectins. Usually,
plant O-glycans attached to serine residues are short,
composed of galactopyranosides present either as mono-
saccharides or as 1®3-linked disaccharides [10,11]. In
general, information about plant O-glycosylation enzyme
machinery is lacking.
In contrast to plants, mammalian O-glycosylation is a
well understood posttranslational modification. Substitu-
tions of serine and threonine residues with sugars such
as fucose, galactose and N-acetylglucosamine are com-
mon modification on mammalian proteins [12], but the
most abundant O-glycans in mammalian cells are mucin
type O-linked glycans. They are represented by structu-
rally diverse oligosaccharides attached through N-acetyl-
galactosamine (GalNAc) to serine and/or threonine
residues. Besides the initial GalNAca-Ser/Thr, known as
Tn antigen, other structures, including core 1 or T anti-
gen (Galb1-3GalNAca-Ser/Thr), core 2 (GlcNAcb1- 6
[Galb1-3]GalNAca-Ser/Thr), core 3 (GlcNAcb1-3Gal-
NAca-Ser/Thr), core 4 (GlcNAcb1-6[GlcNAcb1-3)Gal-
NAca-Ser/Thr), core 5 (GalNAca1-3GalNAca-Ser/Thr),
core 6 (GlcNAcb1-6GalNAca-Ser/Thr), and core 8
(Gala1-3 GalNAca-Ser/Thr), are also commonly linked
to human proteins. These core structures can undergo
further extension and branching to form more highly
complex O-glycans [13].
Mucin type O-linked glycans are synthesized in the
Golgi apparatus [14] in a stepwise and consensus motif-
independent manner. A family of UDP-GalNAc poly-
peptide:N-acetyl-a-galactosaminyltransferases (GalNAc-
Ts, EC 2.4.1.41) initiates the process by transferring
N-acetylgalactosamine (GalNAc) from the charged sugar
donor, UDP-GalNAc, to the hydroxyl group of serine
and threonine amino acid residues (GalNAca1-O-Ser/
Thr). Abundance of GalNAc-T isoforms (at least 24 in
humans [15] and 18 in mice [16]), distinct spatial and
temporal gene expression patterns [16] and unique sub-
strate specificities [17-21] ensure precise selection of
attachment sites and fine regulation of GalNAc glycosy-
lation of fully folded proteins. Depending on the final
O-glycan structure, different sets of glycosyltransferases
participate in elongation of the initial GalNAc residue.
For example, UDP-Gal:GalNAca-Ser/Thr b1-3 galacto-
syltransferase and UDP-GlcNAc:GalNAca-Ser/Thr b1-3
N-acetylglucosaminyltransferase are required for synth-
esis of core 1 O-glycans and core 3 O-glycans,
respectively.
A previous study reported attachment of core 1
Galb1-3GalNAc disaccharide to rice glutelin basic subu-
nits [22], however our in silico analysis and more recent
experimental data [23] suggest that plants do not have
the enzyme machinery to support mucin type O-glyco-
sylation. In light of this, we reasoned that genetic
manipulations could potentially modify plants for pro-
duction of mammalian glycoproteins with homogenous
O-glycan structures.
The present study tested, for the first time, the feasi-
bility of generating a plant-based platform for produc-
tion of Tn antigen-containing proteins/peptides. Many
valuable pharmaceuticals, such as immunomodulators
and tumor-associated antigens essential for the develop-
ment of anticancer therapeutic vaccines, are GalNAc
-glycosylated [24,25]. Despite a growing demand for
these products, manufacturing remains difficult and
costly. In our study, we first addressed the question of
whether the initiation of mucin type O-glycosylation in
plants could be performed with the precision typical of
mammalian cells. Therefore, one of the well character-
ized isoforms of the human GalNAc-Ts family, GalNAc-
T2, was stably expressed in N. benthamiana and used to
demonstrate that mammalian GalNAc-Ts retain their
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functionality, specificity and localization in plant cells.
We further tested the engineered GalNAc-T2 transgenic
plants for their ability to produce GalNAc-glycosylated
proteins. A model glycoprotein, mucosally targeted
mucin 1 (MUC1) tandem repeat-derived peptide, was
transiently expressed using the magnICON decon-
structed viral vector system to ensure rapid accumula-
tion and high yield [26]. Glycosylation efficiency was
monitored by lectin chromatography. Our results
suggest that co-expression of genes for UDP-GalNAc
polypeptide:N-acetyl-a-galactosaminyltransferase, UDP-
GlcNAc 4-epimerase, and UDP-GalNAc transporter are
required to achieve efficient plant-based production of
GalNAc-glycosylated proteins.
Results
Generation and molecular analyses of N. benthamiana
L. plants expressing human GalNAc-T2
Agrobacterium-mediated transformation of N. benthami-
ana L. with pH7WG2:GNT2 binary vector (Fig. 1A) was
performed to generate plants stably expressing human
GalNAc-T2 gene. The putative transgenic plants were
subjected to routine molecular analyses, including PCR,
RT-PCR and Western blotting, to select for the best
producers. Plants that exhibited the expected PCR pro-
duct of 1.7 kb in size (Fig. 1B), RT-PCR band of 0.96 kb
in size (Fig. 1C), and a polypeptide of ~ 65 kDa after
probing with monoclonal antibodies raised against the
full length GalNAc-T2 protein (Fig. 1D) were selected
for further experiments. None of the transgenic plants
had apparent morphological abnormalities (data not
shown).
Localization of human GalNAc-T2 expressed in
N. benthamiana L
A fusion with Aequorea victoria green fluorescent pro-
tein (GFP), positioned at the C terminus of GalNAc-
T2 to avoid interfering with the transmembrane
domain (TMD), was used to monitor the localization
of mammalian enzyme in tobacco cells. A discrete
punctuate pattern was observed by confocal micro-
scopy (Fig. 2A, B). This pattern could be indicative of
Golgi localization or for targeting to the plant preva-
cuolar or late endosomal compartments (PVCs), as
shown by experiments with tobacco Bright Yellow -2
cells expressing fluorescent markers [27]. To better
define the localization of the expressed human Gal-
NAc-T2, plant leaves were treated with Brefeldin A.
Brefeldin A is a macrocyclic lactone isolated from
Alternaria carthami known to block protein ER to
Golgi transport. In plants, the drug causes loss of
Golgi-based vesicle formation and fusion of the indivi-
dual Golgi cisternae with the ER [28]. It also affects
PVCs morphology leading to extensive aggregation and
tubulation. However, in contrast to the high sensitivity
of the Golgi apparatus, PVCs respond to Brefeldin
A treatment only at drug concentrations greater than
50 μg/ml [27].
Figure 1 Representative molecular analyses of N. benthamiana L. GalNAc-T2 transgenic plants. A - Schematic diagram of T-DNA of
pH7WG2:GNT2 plant binary expression vector. Abbreviations: LB, left border; RB, right border; Pnos, nopaline synthase promoter; P35 S, CaMV 35
S promoter; hpt, hygromycin phosphotransferase gene; Tnos, 3’ termination signal of nopaline synthase gene; T35 S, 3’ termination signal of
CaMV 35 S gene; B - PCR screen using 1 μg genomic DNA as a template and primers G1/G2 (see “Materials and Methods”) amplifying human
GalNAc-T2 gene (1.7 kb); C - RT-PCR using 0.5 μg total RNA as a template and primers G3/G4 (see “Materials and Methods) that amplify a 0.96 kb
fragment of the GalNAc-T2 transcript; D - Western blot of total hydrophobic proteins probed with antibodies raised against human GalNAc-T2; E
- The same protein samples separated by SDS-PAGE (4-20% gradient gel) after staining with Coomassie Brilliant Blue R-250; Abbreviations used: C
- control plant; 1,2 - putative transgenic plants; M- markers: Promega 1 kb DNA ladder (B, C), BioRad Kaleidoscope prestained standards (D, E).
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Tobacco plant leaves expressing GalNAc-T2:GFP
fusion protein were incubated for 1 h with 10 μg/ml
Brefeldin A. The treatment caused loss of the bright
green spots and replacement of the punctuate pattern
with a network-type fluorescence (Fig. 2C, D). These
results strongly suggest that mammalian GalNAc-T2 is
retained in the Golgi in plant cells.
Functionality of human GalNAc-T2 expressed in N.
benthamiana L
To assess the functionality of the plant-expressed
human GalNAc-T2, we used an in vitro assay that
included plant microsomal fraction as an enzyme
source, UDP-GalNAc as the donor, and the 113-136 aa
fragment of human chorionic gonadotropin b-subunit
(hCG-b) as an acceptor peptide. Under the chosen
HPLC conditions, the retention time for UDP-GalNAc
was 4.09 min, while hCG-b peptide eluted at 14.08/
14.43 min as two peaks ("a” and “a’ “), as confirmed by
MALDI (data not shown). HPLC separation of an ali-
quot of the enzymatic reaction with the microsomal
fraction from control tobacco plants showed the pre-
sence of only the non-glycosylated hCG-b peptide (Fig.
3A). The observation was further confirmed by MALDI
analysis (data not shown). In contrast, when microsomal
fraction of GalNAc-T2 transgenic plants was used as the
enzyme source, two additional peaks ("b” and “c”) with
slightly shorter retention times were visible on the chro-
matogram (Fig. 3B). Correlation between the accumu-
lated radioactive label in the fractions corresponding to
peaks “b” and “c” and the amount of enzyme added to
the reaction mixture suggested that these peaks
Figure 2 Localization of human GalNAc-T2 expressed in N. benthamiana L. by confocal microscopy. Image of leaf (guard cells) stably
expressing GalNAc-T2:GFP fusion protein: A - image without chloroplasts, B - image with chloroplasts. Image of leaf (guard cells) stably
expressing GalNAc-T2:GFP fusion protein after 1 h treatment with 10 μg/ml Brefeldin A: C - image without chloroplasts, D - image with
chloroplasts. The green signal represents fluorescence of GalNAc-T2:GFP fusion protein, the red signal represents the autofluorescence of
chloroplasts.
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represent products of the enzymatic reaction (Fig. 3C).
Further MALDI-TOF MS analysis of the combined “b”
and “c” fractions revealed three major [M+H]+ ions at
m/z 2491.3, 2694.4, and 2897.5 (Fig. 4A). The ion at m/
z 2491.3 indicated that the analyzed sample contained
the initial (non-glycosylated) acceptor peptide. This was
not surprising since the peak of the acceptor hCG-b
peptide (peak “a”) partially overlapped peaks “b” and “c”.
The ions at m/z 2694.4 and m/z 2897.5 were suggestive
of two glycosylated forms of hCG-b peptide with
Figure 3 Functional analyses of human GalNAc-T2 expressed in N. benthamiana L. plants. GalNAc-T2 enzyme assay was set up in a final
volume of 100 μl with UDP-GalNAc as the donor, and the hCG-b peptide as an acceptor (see “Materials and Methods”). A sample corresponding
to 25 μl of the reaction mixture containing microsomal fraction of A - control plants, or B - GalNAc-T2 transgenic plants as an enzyme source,
was subjected to RP-HPLC as described (see “Materials and Methods”): a - peak corresponding to the hCG-b peptide, b, c - peaks corresponding
to the glycosylated forms of hCG-b peptide; C - monitoring the attachment of GalNAc to the hCG-b peptide by radioactive enzyme assay using
[3H]UDP-GalNAc as a donor and 41 μg (●),, 20.5 μg (■) or 10.25 μg (▲) microsomal proteins from GalNAc-T2 plant, or 41 μg microsomal proteins
from control plant (○) as an enzyme source. Aliquots of 0.5 ml from the collected fractions (2 ml fraction volume) were used to monitor the
radioactivity.
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Figure 4 Functional analyses of human GalNAc-T2 expressed in N. benthamiana L. plants. A - MALDI-TOF MS of glycosylated products
(peaks b + c combined) of hCG-b peptide; B - MALDI-TOF/TOF MS spectrum of [M+H+] 2694.4 corresponding to the monoglycosylated hCG-b
peptide - GalNAc is attached to Ser-15 (corresponding to Ser-127 of hCG-b); C - MALDI-TOF/TOF MS spectrum of [M+H+] 2897.5 corresponding
to the diglycosylated hCG-b peptide - GalNAc is attached to Ser-9 and Ser-15 (corresponding to Ser-121 and Ser-127 of hCG-b, respectively).
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attached one or two GalNAc residues. MALDI-TOF-
TOF spectra analysis further supported the assumption.
The major fragmentation product resulting from loss of
one HexNAc residue from the glycosylated peptide con-
taining a single GalNAc was evidenced by the abundant
ion at m/z 2491.4 (Fig. 4B). Similarly, during the frag-
mentation of the ion at m/z 2897.5 corresponding to the
hCG-b peptide with two GalNAc residues, the massive
peak envelope centered at m/z 2694.4 and smaller peak
envelope at m/z 2491.3 are indicative of the loss of one
and two HexNAc residues, respectively (Fig. 4C).
De-novo peptide sequencing on MALDI-TOF/TOF
MS spectrometer was employed to determine the posi-
tion of the attached GalNAc residues. Based on b- and
y-ions generated during the sequencing, the attachment
of GalNAc for the mono- and diglycosylated peptides
most likely occurred at Ser-15 (corresponding to Ser-
127 of hCG-b; Fig. 4B), and at Ser-9 (corresponding to
Ser-121 of hCG-b) and Ser-15 (Fig. 4C), respectively.
Effect of the expression of human GalNAc-T2 on
glycosylation status of N. benthamiana L. endogenous
proteins
The substrate preferences of GalNAc-T2 have been
extensively studied and the most favorable amino acids
at positions -3, -2, -1, 1, 2, and 3 relative to the site of
glycosylation (Ser/Thr), have been determined [29]. The
first three amino acids with the highest enhancement
values for each of these positions were used to design a
series of peptides consisting of 7 amino acids. In silico
analyses using the peptides to search NCBI plant data-
bases (http://www.ncbi.nlm.nih.gov) indicated that some
annotated plant proteins known to transport through
the ER-Golgi pathway do contain potential sites for Gal-
NAc-glycosylation (data not shown). Therefore, we
tested for possible attachment of GalNAc to endogenous
proteins of N. benthamiana L plants engineered to
express human GalNAc-T2. Equal amounts of soluble
proteins from the control and transgenic plants were
subjected to affinity chromatography on Vicia villosa
agglutinin (VVA)-agarose. VVA is a lectin that strongly
recognizes terminal GalNAc residues attached to serine
or threonine in a polypeptide. The binding buffer was
supplemented with 0.1 M NaCl to prevent non-specific
interactions, and the resin was thoroughly washed
before the elution. Eluted proteins were further sub-
jected to lectin blot analysis with alkaline phosphatase-
conjugated VVA. Several positive bands were detected
in the transgenic plant sample, but not in the negative
control (Fig.5A). Following silver staining, the strongest
band, corresponding to a 33 kDa polypeptide (Fig. 5A,
denoted by an asterisk), was digested with chymotrypsin.
Analysis of the recovered peptides by nano LC-MS/MS
using a linear quadrupole ion trap mass spectrometer
and a database search identified the band with 99%
probability as Nicotiana endochitinase (GenBank Acces-
sion No P24091; EC 3.2.1.14; - Fig. 5B, Table 1). Modifi-
cation of threonine at position 119 by 203 amu was also
detected (Fig. 5C, Table 1), as evidenced by a series of y
ions (y4 through y14 ) containing the modification, thus
strongly suggesting attachment of a N-acetylhexosamine
residue to the polypeptide chain. It is of interest that
cleavage on the carboxy-terminal side of the potentially
modified Thr-119 was absent (lack of y3 and b13 ions),
possibly as a result of the sugar moiety blocking access
of the ionizing mobile proton at that position. Loss of
the sugar moiety from glycopeptides is often observed
during MS/MS, but in certain cases of low-energy-colli-
sion induced dissociation the sugar moiety may remain
attached, resulting in fragment ions carrying the modifi-
cation [30].
A homology model of tobacco endochitinase (Fig. 5D),
built based on the three dimensional structure of O.
sativa L. japonica class I chitinase (pdb ID 2DKV, 66.
1% identity), suggests that Thr-119 should be located on
the surface of the catalytic domain, therefore accessible
for glycosylation. Previous study has shown that Thr-
119 is not directly involved in the catalytic act [31].
Efficiency of attachment of GalNAc to the model protein,
E. coli enterotoxin B subunit:human MUC1 tandem
repeat-derived peptide fusion protein expressed
transiently in GalNAc-T2 plants by magnICON
deconstructed viral vector system
As the transgenic GalNAc-T2 plants demonstrated cap-
ability for attaching GalNAc to the endogenous endo-
chitinase, we further examined their potential to
glycosylate a model protein expressed at high levels. A
synthetic gene coding for a C-terminal His-tagged fusion
between the E. coli enterotoxin B subunit and human
MUC1 tandem repeat (TR)-derived peptide (LTBMUC1)
was used for this purpose (Fig. 6A). Mucins are heavily
glycosylated membrane-bound proteins containing ser-
ine and threonine-rich TRs that are often polymorphic
and vary in number [32]. In most cancers of glandular
epithelial origin, MUC1 is overexpressed and aberrantly
glycosylated, leading to exposure of highly immunogenic
truncated carbohydrate structures [33]. Tn antigen is
one of the most common among them, and some stu-
dies have already demonstrated the potential of MUC-1
TR-derived GalNAc-glycopeptides for active immu-
notherapy of cancer patients [34,35].
The MUC1 TR-derived peptide used as a part of the
model LTBMUC1 protein has seven potential O-glyco-
sylation sites predicted in silico by NetOGlyc (Ser-131,
Thr-132, Thr-140, Ser-141, Thr-145, Ser-151, and Thr-
152), but only serine and threonine in GSTAP motif
(Ser-131, Thr-132, Ser-151, and Thr-152) and threonine
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in GVTSA motif (Thr-140) have been verified experi-
mentally as target sites of GalNAc-T2 [36], (Fig. 6A).
Therefore, upon a complete GalNAc-glycosylation by
GalNAc-T2, the molecular mass of the recombinant
protein should increase by ~ 1 kDa, which is difficult to
resolve during electrophoresis to differentiate the glyco-
sylated and non-glycosylated forms. However, the forms
can be distinguished by exploiting differences in their
affinity to a GalNAc-specific lectin. Accordingly, the
strategy to verify LTBMUC1 glycosylation was designed
as follows: (i) transient expression of the model protein
using the magnICON deconstructed viral vector system
to ensure rapid accumulation and high yield [26]; (ii)
purification by Ni2+ Sepharose Fast Flow chromatogra-
phy combined with a His tag-based screen to detect the
fractions containing the recombinant protein; (iii) affi-
nity chromatography on VVA agarose to capture the
GalNAc-glycosylated population of LTBMUC1, assisted
by a His-tag-based and VVA-lectin blot detection to
verify the molecular mass of the captured protein; (iv)
LC-MS/MS analysis to confirm the identity of
LTBMUC1 and determine the sites of glycosylation.
Leaves of the GalNAc-T2 transgenic tobacco plants
were transiently transformed with the magnICON 3′
vector module pICH11599:LTBMUC1 co-delivered with
the 5′ module pICH15879 and the integrase module
Figure 5 Glycosylation of endogenous N. benthamiana L. proteins upon ectopic expression of human GalNAc-T2. A - VVA-lectin blot of the
soluble proteins bound to VVA-agarose from control (C) and transgenic (GalNAc-T2) plants, and the corresponding silver staining for the GalNAc-
T2 plant sample; B - sequence of tobacco endochitinase (GenBank Accession No P24091) identified with the 33 kDa band denoted in A by an
asterisk: the signal peptide is underlined, the propeptide is double underlined, the covered regions after LC-MS/MS analysis of the chymotryptic
fragments are gray-highlighted, the modified Thr-119 by 203 amu is red-highlighted; C - MS/MS analysis confirming the attachment of GalNAc
(203 amu) to Thr-119; D - homology model of tobacco endochitinase built based on the 3 D structure of O. sativa L. japonica class I chitinase
(pdb ID 2DKV); the position of the glycosylated Thr-119 is denoted by halos.
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pICH14011 [26]. Because of rapidly developed necrosis
leaves were harvested relatively early at 7 day post-infil-
tration. The levels of LTBMUC1 at that time were 3%
of the total soluble proteins at most (Pinkhasov et al.,
submitted). Following protein extraction and ammonium
sulfate precipitation, the His-tagged recombinant protein
was purified by chromatography on Ni2+ Fast Flow
Sepharose. Aliquots of the fractions eluted from the col-
umn were analyzed for purity by Ponceau S staining and
by Western blotting to detect the His-tag on
LTBMUC1. The recombinant protein was not visible on
the Ponceau S-stained PVDF membranes, probably
because its amount was below the detection limit of the
stain (1 μg/5 mm band). It should be noted that the
LTBMUC1-positive fractions contained co-eluted endo-
genous tobacco proteins (Fig. 6B, left side, lower panel).
The main contaminant appears to be the enzyme ribu-
lose-1,5-bisphosphate carboxylase/oxygenase represented
under denatured conditions by its large (~ 53 kDa) and
small (~15 kDa) subunits. The protein is known to be a
major obstacle in achieving homogenous preparations of
plant-expressed biopharmaceuticals [37].
The theoretical molecular mass of LTBMUC1 is 17.7
kDa, but on the His-tag blots the recombinant protein
migrated as a single ~20 kDa band (Fig. 6B, left side,
upper panel). An ~20 kDa band was also detected upon
expression of LTBMUC1 in control, nontransgenic
N. benthamiana L. plants; this band was positively
stained with Roche Diagnostics DIG Glycan Detection
Kit (Pinkhasov et al., submitted). These data suggest
that plant-expressed LTBMUC1 undergoes glycosylation
by endogenous enzyme activities. The amino acid
sequence of LTBMUC1 lacks consensus motifs for N-
glycosylation (Asn-Xaa-Ser/Thr), but there are several
proline residues in a context favoring their hydroxyla-
tion and subsequent glycosylation [7-9]. Therefore, it is
likely that plant-expressed LTBMUC1 is decorated by
plant-specific O-glycans, arabinogalactans and/or
arabinans.
Lectin chromatography on VVA agarose coupled with
VVA lectin blot and His-tag-assisted detection further
demonstrated that trace amounts of LTBMUC1
expressed in GalNAc-T2 transgenic plants were modi-
fied by GalNAc-glycosylation (Fig. 6C, left side).
Co-expression of GalNAc-T2, UDP-GlcNAc-4 epimerase
and UDP-GalNAc transporter is required for GalNAc-
glycosylation of recombinant proteins expressed in
N. benthamiana L. at high levels
The activity of GalNAc-T is not the only factor affecting
the rate of GalNAc-transfer to serine/threonine residues
on acceptor proteins. The concentration of the UDP-
GalNAc donor and the efficiency of transfer to the
Golgi lumen also contribute to the final outcome. Thus,
we further tested whether a boost in the endogenous
UDP-GalNAc substrate pool or the translocation of
UDP-GalNAc to the Golgi lumen could improve the
efficiency of LTBMUC1 GalNAc-glycosylation. GalNAc-
T2 plants were subjected to another round of transfor-
mation with either the Y. enterocolitica gne gene coding
for the enzyme UDP-GlcNAc 4-epimerase that catalyzes
the epimerization of UDP-GlcNAc to UDP-GalNAc, or
the C. elegans C03H5.2 gene encoding a protein capable
of simultaneous and independent transport of UDP-
GlcNAc and UDP-GalNAc [38]. The double transgenics
were further used for production of LTBMUC1 as
described earlier, and in both cases the efficiency of gly-
cosylation of the recombinant protein showed no
improvement (data not shown). Next, Y. enterocolitica
gne gene and C. elegans C03H5.2 gene were delivered
simultaneously by pBYR:GNE.GT plant binary vector
(Fig. 6D) and expressed successfully in GalNAc-T2
plants as evidenced by the RT-PCR analysis (Fig. 6E).
The model LTBMUC1 protein expressed in the triple
transgenics and purified on Ni2+ Fast Flow Sepharose
(Fig. 6B, right side), was completely retained on the
VVA agarose column, which indicated that it was pre-
sent exclusively as a GalNAc-glycosylated form.
An outline of the analyses of LTBMUC1 expressed in
GalNAc-T2 plants (2) and GalNAc-T2//UDP-GlcNAc
Table 1 LC-MS/MS analysis of in-gel chymotrypsin-
digested N. benthamiana L. 33 kDa endogenous
polypeptide band identified as endochitinase (EC
3.2.1.14, GenBank Accession No P24091)
Peptide sequence MH+ Xcorr dCn
(Y)C*SILGVSPGDNLDC*GNQRSF(G) 2197.29 4.24 0.12
(F)FAQTSHETTGGWATAPDGPY(A) 2095.17 3.98 0.77
(L)NNPDLVATDPVISF(K) 1502.65 3.68 0.79
(F)AQTSHETTGGWATAPDGPY(A) 1948.00 3.56 0.85
(L)GVSPGDNLDC*GNQRSFGN(G) 1894.91 3.54 0.44
(F)FAQTSHETTGGW(A) 1322.37 3.48 0.85
(L)GVSPGDNLDC*GNQRSF(G) 1723.76 3.30 0.31
(Y)NYGPC*GRAIGVDLL(N) 1505.67 3.19 0.60
(Y)NAFINAARSFPGFGTSGD(T) 2032.95 2.94 0.73
(F)INAARSFPGF(G) 1080.22 2.80 0.60
(N)RLPGFGVITN(I) 1074.26 2.69 0.85
(F)GRGPIQISHNY(N) 1242.37 2.67 0.79
(L)LNNPDLVATDPVISF(K) 1615.81 2.63 0.69
(Y)FGRGPIQISHNY(N) 1389.54 2.57 0.85
(V)ITNIINGGLEC*GRG(T) 1474.62 2.51 0.78
(A)FINAARSFPGFGTSGD(T) 1847.77 2.37 0.65
(F)INAARSFPGFGTSGD(T) 1700.59 2.13 0.84
The threonine residue (Thr-119) modified by 203 amu is in boldface type,
carboxymethylated cysteine residues are denoted by asterisks. The amino
acids in parenthesis at the beginning and end of each peptide show the
flanking residue in the entire protein sequence.
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4-epimerase//UDP-GlcNAc/UDP-GalNAc transporter
plants (2′) after Ni2+ Fast Flow Sepharose chromatogra-
phy is presented in Fig. 6C. Identical aliquots of
volume-equalized samples were run in parallel and
assayed (i) before VVA chromatography: by His-tag
blotting to demonstrate that comparable amounts of
LTBMUC1 (2 and 2′) were loaded on the columns
(panel “Hisprobe-HRP detection before VVA agarose”),
and (ii) after elution of the bound proteins from VVA
agarose resin: by VVA lectin blotting to confirm the
attachment of GalNAc to the polypeptide acceptors
(panel “VVA blot after VVA agarose), and by His-tag
blotting to determine the portion of the loaded
LTBMUC1 with affinity to the VVA lectin (panel “Hisp-
robe-HRP detection after VVA agarose). In contrast to
LTBMUC1 expressed in GalNAc-T2 plants, the recom-
binant protein produced in the triple transgenics
showed His-tag signals of comparable intensity before
and after passage through the lectin column and a
strong band upon detection by VVA lectin blotting. In
addition, a slight delay in its electrophoretic mobility
was detected (panel “Hisprobe-HRP detection before
VVA agarose). These results clearly indicate that effi-
cient GalNAc-glycosylation of LTBMUC1 was achieved
only upon expression of the model protein in the Gal-
NAc-T2//UDP-GlcNAc 4-epimerase//UDP-GlcNAc/
UDP-GalNAc transporter plants.
Bound proteins that eluted from the VVA-agarose col-
umn from both LTBMUC1 samples were analyzed by
SDS-PAGE and subsequent silver staining. A strong
Figure 6 Characterization of LTBMUC1 produced in transgenic N. benthamiana L. plants expressing either human GalNAc-T2 or co-
expressing human GalNAc-T2, Y. enterocolitica UDP-GlcNAc-4 epimerase, and C. elegans UDPGlcNAc/UDPGalNAc transporter. A - amino
acid sequence of His-tagged LTBMUC1 fusion protein: MUC1 sequence is underlined, GPGP linker is italisized, experimentally confirmed sites for
attachment of GalNAc by GalNAc-T2 are red-highlighted, covered regions after LC-MS/MS analysis of the chymotryptic fragments are gray-
highlighted; B - purification of LTBMUC1 produced in GalNAc-T2 and GalNAc-T2//UDP-GlcNAc-4 epimerase//UDP-GlcNAc/UPD-GalNAc transporter
plants by Ni2+ Sepharose Fast Flow chromatography: Fractions (1, 2, 3, 4 for LTBMUC1 produced in GalNAc-T2 plants; and 1’, 2’, 3’, 4’ for
LTBMUC1 produced in the triple transgenic plants) eluted from the resin with 20 mM phosphate buffer pH 7.4 containing 0.5 M NaCl and 0.5 M
imidazol, were screened by HisProbe-HRP (upper panels); the same blots were stained in parallel with Ponceau S (lower panels); C - VVA
chromatography of LTBMUC1 produced in the tested plant systems after purification on Ni2+ Sepharose Fast Flow: identical aliquots of the
volume-equalized samples 2 and 2’ were screened by HisProbe-HRP before loading on VVA agarose gel (panel HisProbe-HRP detection before
VVA agarose); bound proteins were eluted from the resin with 50 mM Tris HCl buffer pH 7.4 containing 0.1 M NaCl, 1 mM MgCl2 and 0.3 M
GalNAc, and identical aliquots were screened by HisProbe-HRP (panel HisProbe-HRP detection after VVA agarose), VVA blotting (panel VVA blot
after VVA agarose), and SDS-PAGE with subsequent silver-staining (panel silver staining after VVA agarose); asterisk denotes the position of
LTBMUC1; D - schematic diagram of T-DNA of pBYR:GNE.GT plant binary expression vector. Abbreviations: LB, left border; RB, right border; Pnos,
nopaline synthase promoter; P35 S, CaMV 35 S promoter; nptII, neomycin phosphotransferase gene; gne - Y. enterocolitica UDP-GlcNAc-4-
epimerase gene; UDP-GalNAc - C. elegans UDP-GlcNAc/UDP-GalNAc transporter gene; Tnos, 3’ termination signal of nopaline synthase gene; T35
S, 3’ termination signal of CaMV 35 S gene; TvspB - 3’ termination signal of soybean vegetative storage protein B gene; TrbcS - 3’ termination
signal of Rubisco small subunit gene; TEV HT - etch virus translational enhancer element; E - RT-PCR confirmation of the co-expression of human
GalNAc-T2 (GalNAc-T2), C. elegans UDP-GlcNAc/UPD-GalNAc transporter (transporter), and Y. enetrocolitica UDP-GlcNAc-4 epimerase (gne) in N.
benthamana L. plants using 0.5 μg total RNA as a template and primers G3/G4, GT3/GT4, and GE4/GE5, respectively (see “Materials and Methods).
F - spectrum of a chymotryptic peptide of the 20/21 kDa band denoted in C by an asterisk, assisting in the identification of the band as
LTBMUC1.
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band with a molecular mass of ~20/21 kDa was visible
only in the sample from the triple transgenics (Fig. 6C,
right side, denoted by an asterisk). The band was identi-
fied as LTBMUC1 by chymotryptic digest coupled with
nano LC-MS/MS analysis (Table 2, Fig. 6A, F). Peptides
from the MUC1 region of the recombinant protein were
not recovered, even after alternative in-gel digestion
with other proteinases (trypsin, GluC). Thus, this pre-
vented identification of the GalNAc attachment sites.
Discussion
GalNAc-T2 is one of the best characterized members of
the GalNAc-Ts family that exhibits a very low level of
UDP-GalNAc hydrolase activity [29]. Thus, it was cho-
sen for a proof of concept study to determine if mam-
malian enzymes could be engineered into plants capable
of initiating mucin type O-glycosylation. Our work pro-
vides experimental evidence for several conclusions.
Based on the detected single, sharply defined ~ 65 kDa
band after Western blot analysis of the GalNAc-T2
transgenics, it appears that the human enzyme is stably
expressed in plants and similar to expression in mam-
malian cells the consensus Asn-516/Xaa(Asp)-517/Ser-
518 sequence remains unoccupied by N-glycans [39].
The human GalNAc-T2 appears to retain its Golgi loca-
lization in tobacco cells as evidenced by the GFP-tagging
and alteration of the fluorescence pattern after treat-
ment with Brefeldin A. The latter result corroborates
the idea that some targeting signals and/or targeting
mechanisms might be conserved between plants and
animals [40]. The plant-expressed human GalNAc-T2
enzyme is functional and retains its specificity, as
demonstrated by its ability to glycosylate the 113-136 aa
fragment of hCG-b defined as a GalNAc-T2-specific
acceptor [36] at sites identical to the glycosylation sites
of hCG hormone produced by placental trophoblasts in
late pregnancy [41,42]. Specifically, the attachment of
GalNAc to the hCG-b peptide occurs at serine residues
corresponding to Ser-121 and Ser-127 of the hCG-b
subunit. Our results also suggest that attachment of
GalNAc to Ser-127 precedes the attachment of GalNAc
to Ser-121. To our knowledge, there are no previous
studies addressing the pathway of incorporation of Gal-
NAc in hCG or hCG-b-derived peptides. However, the
work of Sugahara et al. [43] supports our conclusion,
having demonstrated that: (i) Ser-127 defines the car-
boxy border of Ser-121 recognition site; (ii) the context
requirements for Ser-127 to act as an acceptor site are
restricted to the presence of Pro-131 and Ser-132, and
do not include Ser-121; (iii) elimination of Ser-121 by
site-directed mutagenesis does not impair the acceptor
potential of Ser-127. In addition, in contrast to Ser-121,
Ser-127 is N-terminally flanked by an adjacent proline
residue which, according to a model study with a library
of oriented random peptides, defines Ser-127 as the
more favorable site for glycosylation by GalNAc-T2 [29].
In silico analysis suggests that plants do not have
orthologs of human GalNAc-Ts. By a combination of
in vitro radioactive enzyme assay and mass-spectrometry
analysis, our work provides direct experimental evidence
for a lack of endogenous GalNAc-T2 activity in
N. benthamiana L. plants. A similar conclusion was
conveyed indirectly by a study showing absence of
mucin type O-glycans in the hinge region of maize-
produced human IgA1 [23]. Our work further demon-
strates that ectopic expression of human GalNAc-T is
sufficient to “arm” plant cells with the ability to initiate
mucin type O-glycosylation, as evidenced by the appear-
ance of several endogenous proteins with affinity to the
GalNAc-specific lectin, VVA. Furthermore, we provide
MS evidence for the attachment of GalNAc to one of
those proteins, the vacuole-targeted enzyme endochiti-
nase that travels through the ER-Golgi route [31]. These
data suggest that besides the enzyme entity, all other
elements necessary for initiation of mucin type O-linked
glycosylation, including a UDP-GalNAc donor and
protein capable of translocating UDP-GalNAc from
the cytosol into the Golgi lumen, exist in plant cells.
The presence of free UDP-GalNAc in plants has
not been documented so far, but a cytosolic enzyme,
UDP-glucose 4-epimerase capable of converting
UDP-GlcNAc, an abundant plant compound, to UDP-
GalNAc, in addition to its primary substrate, UDP-
glucose, has been identified [38]. A nucleotide sugar
transporter with broader substrate specificity could deli-
ver the activated GalNAc to the Golgi lumen. Such
function is likely to be performed by still unknown
or one (or more) of the identified plant UDP-galactose
transporters [44-46]. Similarly to H. sapiens and
D. melanogaster UDP-galactose transporters [47], the
latter might have the ability to transport UDP-GalNAc
in addition to their primary substrate UDP-galactose.
However, the endogenous plant UDP-GalNAc pool and
UDP-GalNAc transporter activity are apparently low
Table 2 LC-MS/MS analysis of in-gel-chymotrypsin-
digested LTBMUC1 produced in N. benthamiana L. plants
co-expressing human GalNAc-T2, Y. enterocolitica UDP-
GlcNAc-4 epimerase and C. elegans UDP-GlcNAc/UDP-
GalNAc transporter
Peptide sequence MH+ Xcorr dCn
(Y)LTETKIDKL(C) 1060.80 2.69 0.61
(W)NNKTPNSIAAI(S) 1142.84 2.61 0.84
(W)NNKTPNSIAAISM(S) 1361.75 2.37 0.64
(Y)TINDKILSY(T) 1066.36 1.99 0.73
The amino acids in parenthesis at the beginning and end of each peptide
show the flanking residue in the entire protein sequence.
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and could be easily “exhausted” by endogenous
substrates, as only a very small portion of the recombi-
nant LTBMUC1 was subjected to glycosylation. In cor-
roboration of this conclusion, co-expression of human
GalNAc-T2 with Y. enterocolitica UDP-GlcNAc 4-
epimerase and C. elegans UDP-GlcNAc/UDP-GalNAc
transporter resulted in the production of LTBMUC1
exclusively as a glycoform. Altered electrophoretic mobi-
lity of the model protein, and especially its strong binding
to VVA-agarose, are unequivocal proofs for attachment
of GalNAc residue(s) to the polypeptide backbone.
Similar to previous observations with maize-expressed
human IgA1 [23], tobacco-expressed LTBMUC1 also
appears to be decorated by plant-specific glycans
attached to hydroxyproline residues (Pinkhasov et al.,
submitted). This modification explains the discrepancy
between the calculated (17.7 kDa) and the apparent
(~20 kDa) molecular mass of the model protein. Gal-
NAc-glycosylation of LTBMUC1 upon expression in
GalNAc-T2//UDP-GlcNAc 4-epimerase//UDP-GlcNAc/
UDP-GalNAc transporter plants decreases further the
electrophoretic mobility of LTBMUC1. Although the
shift appears to reflect the expected contribution of the
GalNAc residues (~0.2 - ~1 kDa) to the protein mass, it
is difficult to relate that shift to exact numbers of
attached GalNAc residues. Our attempts to gain more
information about the occupancy of the glycosylation
sites failed because of the resistance of MUC1 to LC-
MS/MS-compatible proteolytic cleavage. Therefore, it
remains unclear if the presence of plant specific O-gly-
cans “shielded” some of the GalNAc-attachment sites of
the model protein used in this study. It is also unclear if
these O-glycans might become a source of immunogeni-
city or affect the stability and/or the activity of plant-
produced LTBMUC1. These general issues should be
addressed for any plant-produced O-glycosylated protein
therapeutic. A possible approach to eliminate the attach-
ment of the most common plant-specific O-glycans, ara-
binans and arabinogalactans, to the recombinant
pharmaceuticals, would be to prevent the conversion of
proline to 4-hydroxyproline. The expansion of our
knowledge about plant prolyl-4-hydroxylase family
would allow targeted knockout to eliminate the activity
of a certain member of the family, thereby preventing/
minimizing detrimental effects on the plant develop-
ment. Alteration of the amino acid sequence of the
recombinant proteins targeted for plant-based expres-
sion that aims at elimination of motifs favoring prolyl
hydroxylation [9] could serve as an alternative
approach..
Conclusion
Our work provides the first experimental evidence that
plants can be engineered for production of Tn-antigen-
containing therapeutics by “updating” their enzyme
machinery with UDP-GlcNAc 4-epimerase, UDP-Gal-
NAc transporter and GalNAc-T. Further genetic manip-
ulations could potentially lead to the synthesis of more
complex O-glycans. Thus, plants can become an attrac-
tive alternative platform for production of homogenous
populations of mucin type O-glycosylated recombinant
therapeutics with predictable O-glycan structures. Endo-
genous plant enzyme activities that target directly the
actual sites of O-glycan attachment, serine and threo-
nine residues, are not as abundant as in other heterolo-
gous production systems (e.g. O-mannosyltransferase
activity in yeasts). However, proline residues are often in
proximity to the attachment sites, and some of these
prolines might be in a sequence context favoring their
plant-specific hydroxylation and subsequent glycosyla-
tion. The possibility of “collision” between the plant
O-glycosylation process and the engineered GalNAc-gly-
cosylation process requires careful examination of the
amino acid sequences of mammalian proteins targeted
for plant-based expression, and if necessary and possi-
ble, appropriate alterations to eliminate the risky motifs.
Methods
Construction of plant binary expression vectors
The coding region of Homo sapiens GalNAc-T2 (Gen-
Bank Accession No BC041120) was amplified with Pfu
DNA polymerase (Strategene, La Jolla, CA) using G1
(5′-CACCATGCGGCGGCGCTCGCGGATGC-3′)/G2
(5′-CAGCTACTGCTGCAGGTTGAGCGTGAACTTC-
CACTGCTGCGAAAGGGCC-3′) pair of primers. The
product was separated on 1% agarose gel, gene-cleaned
(QIAquick Gel Extraction, Qiagen, Valencia, CA) and
subcloned in pENTR/D-TOPO vector (Invitrogen, Carls-
bad, CA). Using the Gateway™ technology (Invitrogen,
Carlsbad, CA), the gene was transferred either to
pH7WG2, or to pK7FWG2 plant expression vector [48]
for native or fusion GFP-tagged protein expression,
respectively. The final constructs designated as
pH7WG2:GNT2 and pK7FWG2:GNT2, were verified by
sequencing (Applied Biosystems 377 gel sequencer,
ASU), and transferred by electroporation to A. tumefa-
ciens EHA101 competent cells. Recombinant colonies
were selected on LB plates supplemented with 200 mg/l
spectinomycin.
Caenorhabditis elegans clone (CO3H5.2) coding for
UDPGlcNAc/UDPGalNAc transporter [38], was pur-
chased from Open Biosystems (Huntsville, AL), and
amplified using GT1 (5′-CACCATGGATCGAGCTAAC-
GACACGAGCTC-3′)/GT2 (CGGTACCTCAGGCAT-
TATGAGCTTCGGCTG-3′) set of primers. Yersinia
enterocolitica type 0:8 gne gene coding for UDP-GlcNAc-
4 epimerase was isolated by a PCR approach using GE1
(5′-CACCTCTAGAATGTCTATATTAATTACTGG
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TGGTGCTG-3′)/GE2 (5′-CCGAG CTCCTAACAGT-
TATAACCATTAGGATTCATTTT TTGCC-3′) pair of
primers. Both PCR products were subcloned in pENTR/
D-TOPO vector (Invitrogen, Carlsbad, CA). The internal
XbaI site of the gne gene was eliminated by a site-direc-
ted mutagenesis (QuickChange Multi Site-Directed
Mutagenesis Kit, Stratagene, La Jolla, CA) using GE3
(5′-CTGAACTAGCACATCGAGAGTTAGGTTGG-
TATGC-3′) primer. A shuttle pBY210:GNE:GT vector
containing both C. elegans UDPGlcNAc/UDPGalNAc
transporter gene and Y. enterocolitica gne gene was gen-
erated using a two-step strategy. First, the gne gene was
ligated as an XbaI/SacI fragment into pBYsE1bE2T210
(unpublished, H. Mason; details to be published else-
where) digested with the same restriction enzymes. The
generated vector was then cut open with NcoI and KpnI
for ligation of the transporter gene taken from pENTR/
D:GT as an NcoI/KpnI fragment. The cassette with the
two genes was further excised with AscI and FseI, and
ligated into AscI/FseI digested pBYR-H2gpKDEL-K3
(unpublished, H. Mason; details to be published else-
where), thus producing pBYR:GNE.GT vector. The vec-
tor was electroporated into A. tumefaciens LB4404
competent cells. Recombinant colonies were selected in
the presence of 200 mg/l streptomycin.
The construction of pICH11599:LTBMUC1 vector is
described elsewhere (Pinkhasov et al., submitted). The
vector is the 3′ module of the magnICON deconstructed
viral expression system (ICON Genetics, Halle, Ger-
many), and is delivered simultaneously with the inte-
grase module pICH14011 and the 5′ module
pICH15879. The system, based on the assembly of func-
tional viral replicons in planta, is described in details in
[26]. All module vectors were electroporated into
A. tumefaciens GV3101 competent cells and selected in
the presence of 50 mg/L carbenicillin and 60 mg/L
rifampicin.
Plant transformation
Stable Agrobacterium-mediated transformation of
N. benthamiana L. plants was performed by a standard
protocol [49]. Depending on the vector used, transfor-
mants were selected on MS medium [50] containing
50 mg/L hygromycin or 100 mg/L kanamycin, 500 mg/L
cefotaxime, 1 mg/L BAP and 0.1 mg/L NAA. Developed
shoots were transferred to a phytohormone-free MS
medium containing 50 mg/L hygromycin or 100 mg/L
kanamycin, and 300 mg/L cefotaxime for root forma-
tion. Regenerated plants were transferred from the
Magenta boxes to pots, and further grown under green-
house conditions (26°C, 16L/8D).
Transient transformation in planta was performed by
a syringe infiltration method. The suspensions of Agro-
bacterium cells harboring the expression vectors were
infiltrated in fully expanded leaves of wild type of trans-
genic N. benthamiana L. plants. Bacterial suspensions in
10 mM MES buffer pH 5.6 containing 10 mM MgSO4
were adjusted to either OD600 = 0.2 (for pBYR:GNE.
GT), or OD600 = 0.033 (for each of the three magnI-
CON module vectors). Infiltrated plants were kept in
growth chambers (26°C, 16L/8D) until ready for leaf
harvest.
Molecular analyses of the transgenic plants
A PCR screen of the putative GalNAc-T2 transgenic
plants was performed with GoTaq DNA Polymerase
(Promega, Madison, WI), 1 μg genomic DNA (DNeasy
Plant Mini Kit, Qiagen, Valencia, CA) as a template, and
the same primers and PCR program used for GalNAc-
T2 gene amplification.
Total RNA was isolated with Promega’s SV Total
RNA Isolation System. RT-PCR was performed using a
TITANIUM One-Step RT-PCR Kit (BD Biosciences,
Mountain View, CA), and 500 ng of template. The fol-
lowing pair of primers were used: G3 (5′-GGTGAT-
CACGTTTCACAATGAAGCCAGG-3′)/G4 (5′-AGTGT
CGAGGCAGTTAGTTCCCTGCTGC-3′) pair for ampli-
fication of a 0.96 kb fragment of the human GalNAc-T2
transcript, GT3 (5′-GACACGAGCTCCAATCTGAAG
CTCATCTC-3′)/GT4 (5′- CAGGCATTATGAGCTT
CGGCTGGTGTCG-3′) pair for amplification of a 1.04
kb of C. elegans UDP-GlcNAc/UPD-GalNAc transporter
transcript, and GE4 5′-GTCTATATTAATTACTGG
TGGTGCTGGATATATAGG-3′)/GE5 (5′-CAGTTA-
TAACCATTAGGATTCATTTTTTGCCATTTCCAAG
CGTCC-3′) pair for amplification of 1.07 kb of Y. ene-
terocolitica gne transcript. The PCR and RT-PCR sam-
ples were separated on agarose gels along with
BenchTop 1 kb DNA ladder (Promega, Madison, WI) or
GeneRuler 1 kb DNA ladder (Fermentas Inc., Glen Bur-
nie, MD), and visualized by staining with ethidium
bromide.
For Western blot analysis, the hydrophobic proteins
from the transgenic and control plants’ leaves were iso-
lated with a Hydrophobic Protein Isolation Kit (Sigma,
St. Louis, MO). SDS samples were prepared with 5×SDS
sample buffer (0.2 M Tris HCl pH 6.8, 3.7 M b-mercap-
toethanol, 10% (w/v) SDS, 0.05% (w/v) bromophenol
blue) and loaded on 4-20% gradient gels (BioRad, Her-
cules, CA) next to Kaleidoscope Prestained Standards
(BioRad, Hercules, CA). Separated proteins were electro-
blotted onto 0.45 μm Immobilon-P PVDF membranes
(Millipore, Billerica, MA) and blocked overnight at 4°C
in TBST buffer (20 mM Tris HCl pH 7.4, 180 mM
NaCl, 0.05% (v/v) Tween-20) containing 5% (w/v) dried
milk. Following two washes with TBST for 15 minutes
each, the membranes were probed overnight at 4°C with
mouse monoclonal IgG antibodies (10 μg CB-4 in 5 ml
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TBST containing 1% (w/v) dried milk) raised against
human GalNAc-T2 (CellMab AB, Sweden) as originally
described in [51]. Next day, the blots were washed as
described above, and incubated for 1 hour at room tem-
perature with 1:3000 diluted anti-mouse horse radish
peroxidase-conjugated antibodies. This was followed by
four more washes (2 × 15 min in TBST and 2 × 5 min
in double distilled water), and an ECL detection per-
formed according to the manufacturer (Amersham Bio-
sciences, Piscataway, MA).
GalNAc-T2 enzyme assay
Plant leaves were homogenized with a mortar and pestle
in cold 50 mM Tris HCl buffer pH 7.4 containing 330
mM sucrose, 3 mM DTT, 3 mM EDTA, 5% polyvinyl
pyrrolidone and 1 mM PMSF. The homogenate was fil-
tered through cheesecloth and centrifuged at 10 000 g for
25 minutes at 4°C. The supernatant was then centrifuged
at 100 000 g for 2 hours (Beckman Coulter Optima L-
100 XP Ultracentrifuge). The pellet representing micro-
somal membranes was resuspended in 50 mM Tris HCl
pH 7.4, and protein concentration was measured accord-
ing to the assay described in [52]. The GalNAc-T2
enzyme assay was performed at 37°C in 100 μl reaction
mixture containing 25 mM Tris HCl buffer pH 7.4, 10-45
μg microsomal proteins, 500 μg acceptor peptide (the
113-136 aa fragment of human chorionic gonadotropin
b-subunit, hCG-b, synthesized by the Proteomics and
Protein Chemistry Lab, ASU and verified by mass spec-
trometry), 10 μg UDP-GalNAc or 1.5 μCi [3H]UDP-Gal-
NAc (American Radiolabeled Chemicals, St. Louis, MO),
10 mM MnCl2, and 0.25% (v/v) Triton X-100. At the
completion of the reaction, the mixture was filtered
sequentially through Ultrafree-MC centrifugal filter
(Millipore, Bedford, MA) and Nanosep 30 K filter spin
columns (Pall Corporation, East Hills, NY).
Identification of the reaction products by mass-
spectrometry (MS) and peptide sequencing
An aliquot of the reaction mixture was subjected to
reverse-phase HPLC (Agilent 1100 system, Waters, Mil-
ford, MA) using Luna column (C18, 5 μm, 10 × 250
mm; Phenomenex, Torrance, CA). The compounds
were eluted at a constant flow rate of 4 ml/min with a
linear (10-45%) gradient of solvent B (0.1% trifluoroace-
tic acid (TFA), 90% acetonitrile in water) in solvent A
(0.1% TFA in water) for 20 minutes, followed by a linear
gradient (45-95%) of solvent B in solvent A for 10 min.
The elution of the peptides was monitored by diode-
array detector at 214 nm. Fractions of 2 ml were col-
lected throughout and monitored for incorporated
radioactivity on a LS 6500 Multipurpose Scintillation
Counter (Beckman Coulter, Fullerton, CA). Alterna-
tively, the peaks were collected and subjected to a
matrix-assisted laser desorption ionization time of flight
(MALDI -TOF) MS. One microliter from each peak
fraction was mixed with 9 μl matrix solution (a satu-
rated solution of a-cyano-4-hydroxycinnamic acid and
0.1% TFA in 50% acetonitrile in water), and 1 μl of this
mixture was spotted on a stainless steel plate. Mass
spectra were acquired in positive ion mode with the
reflector engaged on Bruker Daltonix Ultraflex III TOF/
TOF mass spectrometer (Bruker, Billerica, MA). The
Nd:YAG laser (355 nm) intensity was adjusted for opti-
mum sensitivity and resolution. Single stage MALDI-
TOF mass spectra were externally calibrated with a mix-
ture of 7 peptides supplied by Bruker, ranging in monoi-
sotopic m/z from 1046.54 (Angiotensin II) to 3147.47
(Somatostatin). The acceleration voltage was as follows:
ion source 1 - 25.00 kV, ion source 2 - 21.90 kV, lens -
9.50 kV, reflector 1 - 26.30 kV, reflector 2 - 13.80 kV.
Glycosylated hCG-b peptides′ sequencing (TOF/TOF
MS spectra) provided clear spectra with readily available
-b/-y-ions that were analyzed with the Brukers’ BioTools
version 3.0 software.
Purification of LTBMUC1 fusion protein
LTBMUC1 fusion protein was extracted from tobacco
leaves by homogenization with cold 50 mM Tris HCl
buffer pH 7.4 containing 0.1 M NaCl, 1 mM MgCl2,
3 mM DTT, and 1 mM PMSF. The homogenate was
run through cheesecloth and centrifuged at 10 000 × g
for 15 minutes at 4°C. The supernatant was saturated
with (NH4)2SO4 to a final concentration of 75% (w/v)
and incubated overnight at 4°C. The precipitated pro-
teins were collected by centrifugation at 15 000 g for
45 min and 4°C, and the pellet was dissolved in a
small amount of 50 mM Tris HCl buffer pH 7.4 con-
taining 1 mM MgCl2. The samples were desalted using
PD10 columns (Amersham Biosciences, Piscataway,
MA), supplemented with NaCl to a final concentration
of 0.1 M, and subjected to chromatography on Ni2+
Fast Flow Sepharose (Amersham Biosciences, Piscat-
away, MA) according to manufacturer’s recommenda-
tions. The eluted fractions were screened for the
presence of the recombinant LTBMUC1 protein by
SuperSignal West HisProbe Kit (Pierce, Rockford, IL).
Blots were stained in parallel with Ponceau S (Sigma,
St. Louis, MO).
Lectin Analysis
Soluble proteins from tobacco leaves of the wild type or
transgenic plants were extracted and (NH4)2SO4-precipi-
tated as described above. After desalting using desalting
spin columns (Pierce, Rockford, IL), 150 μl samples of
total soluble proteins or purified LTBMUC1 normalized
by Bradford assay [52] and Western blot/Densospot
reading, respectively, were mixed in Zeba spin columns
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(Pierce, Rockford, IL) with equal volume of Vicia villosa
(VVA) immobilized lectin gel (EY Laboratories, San
Mateo, CA) pre-equilibrated with 50 mM Tris HCl buf-
fer pH 7.4 containing 0.1 M NaCl and 1 mM MgCl2.
The suspension was incubated overnight at 4°C on a
Thermoline Labquake shaker. The non-bound proteins
were then collected and the column was washed with 20
column volumes of buffer. Bound proteins were eluted
with 50 mM Tris HCl buffer pH 7.4 containing 0.1 M
NaCl, 1 mM MgCl2 and 0.3 M GalNAc, and used for
further analyses.
SDS samples of VVA agarose-bound proteins were
prepared, and SDS PAGE on 4-20% gradient polyacryla-
mide gels was performed as described earlier. The gels
were either silver-stained using Silver Stain Kit (Pierce,
Rockford, IL), probed with alkaline phosphatase-conju-
gated VVA (EY Laboratories, San Mateo, CA) following
a protocol of Roche Molecular Biochemicals, or sub-
jected to His-tag-based detection using SuperSignal
West HisProbe kit (Pirece, Rockford, IL).
Tandem mass spectrometry coupled to liquid
chromatography (LC-MS/MS)
Following SDS-PAGE and silver staining as described
above, the bands of interest were excised and digested
with chymotrypsin (10 μg/ml) at 37°C overnight. LC-
MS/MS analyses of in-gel chymotrypsin digested protein
bands [53] were carried out using a linear quadrupole
ion trap ThermoFinnigan LTQ mass spectrometer (San
Jose, CA) equipped with a Michrom Paradigm MS4
HPLC, a SpectraSystems AS3000 autosampler, and a
nanoelectrospray source. Peptides were eluted from a
15 cm pulled tip capillary column (100 um I.D. × 360
um O.D; 3-5 um tip opening) packed with 7 cm Vydac
C18 (Hesperia, CA) material (5 μ, 300Å pore size), using
a gradient of 0-65% solvent B (98% methanol/2% water/
0.5% formic acid/0.01% triflouroacetic acid) over a
60-min period at a flow rate of 350 nl/min. The LTQ
electrospray positive mode spray voltage was set at 1.6
kV, and the capillary temperature - at 180°C. Dependent
data scanning was performed by the Xcalibur v 1.4 soft-
ware [54] with a default charge of 2, an isolation width
of 1.5 amu, an activation amplitude of 35%, an activa-
tion time of 30 msec, and a minimal signal of 100 ion
counts. Global dependent data settings were as follows:
reject mass width of 1.5 amu, dynamic exclusion
enabled, exclusion mass width of 1.5 amu, repeat count
of 1, repeat duration of 1 min, and exclusion duration
of 5 min. Scan event series included one full scan with
mass range of 350 - 2000 Da, followed by 3 dependent
MS/MS scans of the nine most intense ions. Dynamic
exclusion was set on with a time window of 5 min. Tan-
dem MS spectra of the peptides were analyzed with
TurboSEQUEST™, a program that allows correlation of
the experimental tandem MS data with the theoretical
spectra generated from known protein sequences [55].
The peak list (data files) for the search was generated by
Bioworks 3.1 SR1. Parent peptide mass error tolerance
was set at 1.5 amu and fragment ion mass tolerance was
set at 0.5 amu during the search. Possible modifications
such as alkylation of cysteine residues and oxidation of
methionine residues as well as other possible modifica-
tions (e.g. +203 Da on threonine and serine residues),
were included in the search parameters. The criteria
that were used for a preliminary positive peptide identi-
fication were the same as previously described, namely
peptide precursor ions with a +1 charge having a Xcorr
>1.8, +2 - Xcorr > 2.5, and +3 - Xcorr > 3.5. A dCn
score > 0.08 and a fragment ion ratio of experimental/
theoretical >50% were also used as filtering criteria for
reliable matched peptide identification [56,57]. All
matched peptides were confirmed by visual examination
of the spectra. All spectra were searched for initial pro-
tein identification against the non-redundant protein
database downloaded from NCBI. The results were also
validated with X!Tandem v. 2007.01.01.1 http://www.
thegpm.org[58] and with Scaffold v. 2.0.3 (Proteome Soft-
ware Inc., Portland, OR), a program that relies on various
search engine results (ie: Sequest, X!Tandem, MASCOT),
and which uses Bayesian statistics to reliably identify
more spectra [59,60]. Peptide and protein identifications
were accepted if the probability was greater than 90.0%
as specified by the Peptide Prophet Algorithm [58] and
the Protein Prophet Algorithm [60], respectively.
Confocal microscopy
Leaves from tobacco plants expressing GalNAc-T2:GFP
fusion protein were cut in half and incubated for 1 h at
room temperature either in 50 mM Pipes buffer, pH 6.9
containing 5 mM EGTA and 5 mM MgSO4, or in the
same buffer supplemented with 10 μg/ml Brefeldin A
(Sigma, St. Louis, MO). Microscope slides were prepared
with small segments of transformed leaves cut with a
razor blade and mounted in water. Imaging was con-
ducted on the Leica SP2 Multi-photon Scanning Laser
Microscope (Leica Microsystems Inc., Bannockburn, IL)
housed in the W.M. Keck Bioimaging Facility at Arizona
State University. Multiple lasers allowed for simulta-
neous imaging of GFP fusion protein (Argon, 488 nm),
and auto-fluorescence given off by the chloroplasts
(Krypton, 568 nm). The detection channels (Ch) were
set to the following ranges: Ch 1: 490-510 nm and Ch 2:
600-720 nm. Settings for gain and offset of the detectors
were kept constant for all experiments. Using a 40× oil
objective, images were scanned at 0.6 μm intervals in
the z-axis. The post-acquisition image processing was
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performed using the Leica SP2 software (Leica Micro-
systems Inc., Bannockburn, IL) and Adobe Photoshop
CS3 software (Mountain View, CA).
In silico analyses
A GenBank/NCBI database http://www.ncbi.nlm.nih.gov
was accessed in February, 2008 - May, 2009. Localiza-
tion of proteins was predicted with PSORT software
http://psort.ims.u-tokyo.ac.jp/form.html. Predictions of
signal sequences and potential mucin type O-glycosyla-
tion sites were done with SignalP 3.0 http://www.cbs.
dtu.dk/services/SignalP/ and NetOGlyc 3.1 http://www.
cbs.dtu.dk/services/NetOGlyc/, respectively. A homology
model of the tobacco endochitinase (GenBank Accession
No AAA34070) was built based on the 3 D structure of
O. sativa L. japonica class I chitinase (pdb ID 2DKV)
using Geno3 D automatic molecular modeling tools
http://pbil.ibcp.fr/htm/index.php and Jmol software
http://molvis.sdsc.edu/fgij/index.htm for visualization.
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